CRISPR Therapeutics (CRSP) Proxy filing summary

Executive summary

• The 2026 Annual General Meeting will be held on June 4, 2026, with shareholders voting on key proposals including financial statements, director elections, compensation, capital structure, and incentive plans.

• Shareholders of record as of April 20, 2026, are eligible to vote, with each share carrying one vote and specific voting restrictions outlined in the Articles of Association.

• The Board recommends voting in favor of all proposals, including the re-election of directors, compensation approvals, and capital increases.

Voting matters and shareholder proposals

• Proposals include approval of 2025 financial statements, appropriation of net loss, discharge of directors and executive committee, re-election of directors and compensation committee, compensation approvals, capital band and conditional capital increases, stock option plan, and auditor re-election.

• Shareholders will vote on both binding and advisory compensation matters, including Swiss and U.S. say-on-pay votes.

• Shareholder proposals and director nominations require at least 0.5% of share capital or voting rights and must be submitted 120 days before the next AGM.

Board of directors and corporate governance

• The Board consists of eleven directors, all standing for re-election for one-year terms, with detailed biographies and qualifications provided.

• The Board has Audit, Compensation, and Nominating Committees, all composed of independent directors.

• The Lead Independent Director role ensures independent oversight, and the Board emphasizes diversity in skills and backgrounds.

• Corporate governance documents, including the Code of Conduct, are available on the company website.